[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]
Autor: | Menif, S., Ben Romdhane, N., Hafsia, R. |
---|---|
Přispěvatelé: | Laboratoire d'hématologie moléculaire et cellulaire (LR11IPT07), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Laboratoire d'hématologie, Hôpital La Rabta [Tunis], Service d'hématologie, hôpital Aziza-Othmana |
Jazyk: | francouzština |
Rok vydání: | 2007 |
Předmět: |
Adult
Male Receptor Platelet-Derived Growth Factor alpha Oncogene Proteins Fusion MESH: Receptor Platelet-Derived Growth Factor alpha [SDV]Life Sciences [q-bio] MESH: Piperazines Piperazines MESH: Hypereosinophilic Syndrome Hypereosinophilic Syndrome MESH: Protein Kinase Inhibitors Humans FIP1L1-PDGFRA Protein Kinase Inhibitors reproductive and urinary physiology MESH: Treatment Outcome mRNA Cleavage and Polyadenylation Factors MESH: Humans MESH: Middle Aged MESH: Adult Middle Aged MESH: Male Pyrimidines Treatment Outcome MESH: Pyrimidines Imatinib Benzamides Imatinib Mesylate biological phenomena cell phenomena and immunity MESH: mRNA Cleavage and Polyadenylation Factors MESH: Oncogene Proteins Fusion |
Zdroj: | La Revue De Médecine Interne La Revue De Médecine Interne, Elsevier, 2008, 29 (1), pp.65-7. ⟨10.1016/j.revmed.2007.09.036⟩ |
ISSN: | 0248-8663 1768-3122 |
Popis: | International audience; Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders characterized by marked peripheral blood and tissue eosinophilia resulting in organ damage. Recent advances in molecular biology have led to the identification of a FIP1L1-PDGFRA fusion gene as a recurrent abnormality in some patients with HES. This fusion gene results from a cryptic 4q12 interstitial deletion involving an 800 kb region. Recent reports indicate that this subtype of HES is imatinib responsive with rapid and complete haematological remissions. Here we report two patients successfully treated with imatinib. |
Databáze: | OpenAIRE |
Externí odkaz: |